Tag archive

final

publicSwissmedic (Swiss Agency for Therapeutic Products) · Switzerland · Updated Jun 22, 2026

Adoption of ICH E6(R3) Annex 2 for Good Clinical Practice

MAHs and trial sponsors must align their safety monitoring and data collection workflows with the new GCP principles established in ICH E6(R3) Annex 2.

Inspection ReadinessCAPARegulatory Intelligence Lead

SOP Impact3 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Notice

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jun 19, 2026

Swissmedic Guidance on Injectable Products for Wrinkle Treatment

Urgency: High

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

Country ComplianceRegulatory Intelligence Lead

SOP Impact1 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Guidance

Read impact briefarrow_forward

publicTherapeutic Goods Administration (TGA) · Australia · Updated Jun 18, 2026

Update to listed medicine ingredients in June 2026

Urgency: High

Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.

Country ComplianceRegulatory Intelligence Lead

SOP Impact1 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Notice

Read impact briefarrow_forward

Get updates for your PV role

Subscribe to impact-first pharmacovigilance updates. Select every role you want in your digest.

Digest roles: QPPV. Work email only